JP2017515508A - 慢性ｂ型肝炎ウイルス（ｈｂｖ）感染症を予防または処置するためのウイルス様ベシクル（ｖｌｖ）ベースのワクチン - Google Patents

慢性ｂ型肝炎ウイルス（ｈｂｖ）感染症を予防または処置するためのウイルス様ベシクル（ｖｌｖ）ベースのワクチン Download PDF

Info

Publication number
JP2017515508A
JP2017515508A JP2017512646A JP2017512646A JP2017515508A JP 2017515508 A JP2017515508 A JP 2017515508A JP 2017512646 A JP2017512646 A JP 2017512646A JP 2017512646 A JP2017512646 A JP 2017512646A JP 2017515508 A JP2017515508 A JP 2017515508A
Authority
JP
Japan
Prior art keywords
hbv
virus
hepatitis
vlv
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017512646A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017515508A5 (cg-RX-API-DMAC7.html
Inventor
マイケル ロベック
マイケル ロベック
ジョン ローズ
ジョン ローズ
トレイシー レイノルズ
トレイシー レイノルズ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University filed Critical Yale University
Publication of JP2017515508A publication Critical patent/JP2017515508A/ja
Publication of JP2017515508A5 publication Critical patent/JP2017515508A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10141—Use of virus, viral particle or viral elements as a vector
    • C12N2730/10143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6072—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses
    • C12N2810/6081—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses rhabdoviridae, e.g. VSV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
JP2017512646A 2014-05-16 2015-05-11 慢性ｂ型肝炎ウイルス（ｈｂｖ）感染症を予防または処置するためのウイルス様ベシクル（ｖｌｖ）ベースのワクチン Pending JP2017515508A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461994166P 2014-05-16 2014-05-16
US61/994,166 2014-05-16
PCT/US2015/030100 WO2015175380A1 (en) 2014-05-16 2015-05-11 VIRUS LIKE VESICLES (VLVs) BASED VACCINES TO PREVENT OR TREAT CHRONIC HEPATITIS B VIRUS (HBV) INFECTION

Publications (2)

Publication Number Publication Date
JP2017515508A true JP2017515508A (ja) 2017-06-15
JP2017515508A5 JP2017515508A5 (cg-RX-API-DMAC7.html) 2018-06-21

Family

ID=54480490

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017512646A Pending JP2017515508A (ja) 2014-05-16 2015-05-11 慢性ｂ型肝炎ウイルス（ｈｂｖ）感染症を予防または処置するためのウイルス様ベシクル（ｖｌｖ）ベースのワクチン

Country Status (8)

Country Link
US (1) US9987353B2 (cg-RX-API-DMAC7.html)
EP (1) EP3143144A4 (cg-RX-API-DMAC7.html)
JP (1) JP2017515508A (cg-RX-API-DMAC7.html)
CN (1) CN106459998A (cg-RX-API-DMAC7.html)
AU (1) AU2015259470A1 (cg-RX-API-DMAC7.html)
BR (1) BR112016026721A2 (cg-RX-API-DMAC7.html)
CA (1) CA2948181A1 (cg-RX-API-DMAC7.html)
WO (1) WO2015175380A1 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023509966A (ja) * 2020-01-10 2023-03-10 カロジェン コーポレイション 腫瘍溶解性ウイルス様小胞の組成物および使用方法
JP2023510589A (ja) * 2020-01-19 2023-03-14 シァメン・イノドックス・バイオテック・カンパニー・リミテッド ＨＢｃＡｇの検出方法及び抗体

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3002508A1 (en) * 2016-01-12 2017-07-20 Ulrike Protzer Means and methods for treating hbv
EP3276006A1 (en) * 2016-07-27 2018-01-31 Theravectys Lentiviral vectors for expression of hepatitis b virus (hbv) antigens
WO2018126042A1 (en) * 2016-12-29 2018-07-05 Virongy L.L.C. Retro- and lenti-hbv hybrid vectors and constructs
CN108949790A (zh) * 2017-10-27 2018-12-07 电子科技大学 一种基于基因工程烟草的1,2,3-三氯丙烷生物降解方法
JP2021522864A (ja) * 2018-05-10 2021-09-02 クリアビー セラピューティクス リミテッド Ｂ型肝炎感染症を処置するための方法および組成物
US20210355168A1 (en) * 2018-10-05 2021-11-18 Rnagene Inc. Chimeric antigen with enhanced multi-immune function through specific binding to target cell, and use thereof
MX2022003658A (es) 2019-09-30 2022-04-25 Gilead Sciences Inc Vacunas contra el virus de la hepatitis b (vhb) y metodos para tratar el vhb.
CN113234692B (zh) * 2021-05-11 2022-02-22 华中农业大学 一种包含狂犬病毒糖蛋白的感染性克隆及应用
CN113736750B (zh) * 2021-09-22 2023-03-31 中牧实业股份有限公司 一株盖他病毒毒株及其应用
WO2023133509A2 (en) * 2022-01-08 2023-07-13 Carogen Corporation Multi-antigen therapeutic vaccines to treat or prevent chronic hepatitis b virus infection
CN119110727A (zh) * 2022-02-22 2024-12-10 卡罗根公司 用于感染性疾病和癌症免疫疗法应用的多功能病毒样囊泡(vlv)平台
CN115747174A (zh) * 2022-09-15 2023-03-07 武汉大学 重组溶瘤病毒rVSVM51R-C在乙肝性肝癌中的应用
KR20250103763A (ko) * 2022-11-07 2025-07-07 시아먼 유니버시티 융합 단백질 및 이를 포함하는 입자형 항원

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100322965A1 (en) * 2008-01-11 2010-12-23 Rose John K Viral vaccine vectors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030099932A1 (en) 1998-05-12 2003-05-29 Lorens James B. Retroviral vectors with separation sequences
ES2170622B1 (es) * 1999-12-03 2004-05-16 Consejo Superior De Investigaciones Cientificas Clones y vectores infectivos derivados de coronavirus y sus aplicaciones.
JP2009511636A (ja) * 2005-10-18 2009-03-19 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド アルファウイルスレプリコン粒子による粘膜免疫および全身免疫
AU2015259472A1 (en) * 2014-05-16 2016-11-10 Yale University Evolution of high-titer virus-like vesicles for vaccine applications

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100322965A1 (en) * 2008-01-11 2010-12-23 Rose John K Viral vaccine vectors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
VIROLOGY, vol. 218, JPN6019027494, 1996, pages 406 - 411, ISSN: 0004077215 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023509966A (ja) * 2020-01-10 2023-03-10 カロジェン コーポレイション 腫瘍溶解性ウイルス様小胞の組成物および使用方法
JP2023510589A (ja) * 2020-01-19 2023-03-14 シァメン・イノドックス・バイオテック・カンパニー・リミテッド ＨＢｃＡｇの検出方法及び抗体

Also Published As

Publication number Publication date
EP3143144A1 (en) 2017-03-22
CA2948181A1 (en) 2015-11-19
AU2015259470A1 (en) 2016-11-10
US9987353B2 (en) 2018-06-05
WO2015175380A1 (en) 2015-11-19
BR112016026721A2 (pt) 2017-10-31
EP3143144A4 (en) 2017-12-20
US20170056493A1 (en) 2017-03-02
CN106459998A (zh) 2017-02-22

Similar Documents

Publication Publication Date Title
US9987353B2 (en) Virus like vesicles (VLVS) based vaccines to prevent or treat chronic hepatitis B virus (HBV) infection
US11478543B1 (en) Coronavirus disease (COVID-19) vaccine
KR20230025670A (ko) Sars-cov-2 백신
US11478544B2 (en) Chimeric hepatitis D virus antigen and hepatitis B virus pre S1 genes for use alone or in vaccines contaning hepatitis B virus genes
DK2989205T3 (en) Bacterial artificial chromosomes
US10435712B2 (en) Evolution of high-titer virus-like vesicles for vaccine applications
JPWO2012053646A1 (ja) ワクシニアウイルスベクターおよびセンダイウイルスベクターからなるプライム／ブーストワクチン用ウイルスベクター
EP4205762A1 (en) Improved dna vaccine for sars-cov-2
JP2019501945A (ja) インフルエンザワクチン接種のための方法および組成物
WO2021251453A1 (ja) 核酸脂質粒子ワクチン
AU2013203696A1 (en) Recombinant Viral Vectors and Uses Therefor
JP2023516149A (ja) コロナウイルスワクチン
JP2021500880A (ja) ２つの発現カセットを有するサルアデノウイルスベクター
US20250121052A1 (en) Sars-cov-2 vaccines
US20240181041A1 (en) Adenovirus SARS-CoV-2 Vaccine
Zhou et al. Vaccination with a fusion DNA vaccine encoding hepatitis B surface antigen fused to the extracellular domain of CTLA4 enhances HBV-specific immune responses in mice: implication of its potential use as a therapeutic vaccine
Feng et al. The development of persistent duck hepatitis B virus infection can be prevented using antiviral therapy combined with DNA or recombinant fowlpoxvirus vaccines
JP2022536850A (ja) Ｂ型肝炎ウイルス（ｈｂｖ）ワクチンおよび抗ｐｄ－１または抗ｐｄ－ｌ１抗体の組合せ
JP2022537324A (ja) Ｂ型肝炎ウイルス（ｈｂｖ）ワクチンおよび抗ｐｄ－１抗体の組合せ
TWI906499B (zh) 一種治療ｂ型肝炎的慢病毒載體、慢病毒顆粒及其製備方法和應用
AU2022354279A1 (en) Pancoronavirus vaccines
WO2025133030A1 (en) Prime-boost immunization against influenza
HK40074915B (zh) 一种治疗乙型肝炎的慢病毒载体、慢病毒颗粒及其制备方法和应用
WO2020214203A1 (en) Replication deficient adenoviral vectors for hiv vaccine applications

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180508

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180508

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190717

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200302